-

Thermo Fisher Scientific Launches Rapid Environmental PCR Testing Solution That Detects In-Air SARS-CoV-2 Pathogens

Rapid testing produces air sample results in 30 minutes

FRANKLIN, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., today announced the launch of a new rapid environmental test to help in the fight against COVID-19. The Thermo Scientific Renvo Rapid PCR Test is the latest solution in the company’s in-air pathogen surveillance product portfolio. The Renvo Rapid PCR Test is performed on air samples collected using the company’s Thermo Scientific AerosolSense Sampler.

The Renvo Rapid PCR Test is designed for environmental surveillance only, rather than diagnostic purposes, in communal locations such as schools, businesses, healthcare facilities, government buildings and other public areas. This easy-to-use solution provides fast, highly accurate detection of SARS-CoV-2 pathogens through indoor air sampling, enabling users to perform SARS-CoV-2 testing of air samples on- site, without the need for specialized training or sending samples to a lab for analysis.

The system uses proprietary Oscar PCR technology to shorten thermocycling times and produce on-site SARS-CoV-2 air sample results in just 30 minutes, a marked improvement over the four to 24-hour testing turnaround time previously available using the AerosolSense Sampler testing service. This faster response time enables quick decision making and strengthening of risk mitigation strategies for communal locations and facilities.

“As the world learns to live with COVID-19 and adapts to the rapidly changing dynamics of new variants, there is a clear need for heightened surveillance and testing of indoor air quality,” said Siqi Tan, vice president and general manager of environmental and process monitoring at Thermo Fisher. “For facilities that already have our AerosolSense Samplers, the Renvo Rapid PCR Test can be used as an accessory to strengthen their testing processes. The powerful combination of the AerosolSense Sampler and the Renvo Rapid PCR Test offers fast, highly accurate environmental surveillance for SARS-CoV-2 for greater peace of mind.”

The Renvo Rapid PCR Test is the latest addition to Thermo Fisher’s overall response to COVID-19, which includes other PCR testing solutions, virus and epidemiological research, vaccine development and lab products.

For more information, visit www.thermofisher.com/renvo.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Media Contact Information:
Becca Quine
Account Manager
Phone: +44 1480 405 333
E-mail: rebeccaq@kdm-communications.com

Thermo Fisher Scientific Inc.

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Summary
Renvo Rapid PCR Test for AerosolSense Sampler

Contacts

Media Contact Information:
Becca Quine
Account Manager
Phone: +44 1480 405 333
E-mail: rebeccaq@kdm-communications.com

More News From Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Deepens Investment in Asia’s Biopharma Ecosystem with Expansion of Bioprocess Design Centers

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced an expansion of its bioprocessing capabilities across Asia, reinforcing its commitment to supporting the region’s rapidly growing biopharmaceutical industry. The company is introducing a new Bioprocess Design Center in Hyderabad, India, and has expanded its existing Bioprocess Design Centers in Incheon, Korea and Singapore, further strengthening a strategic regional network desig...

Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of €2.1 billion aggregate principal amount (the “Offering”) of the following euro-denominated notes, which will be issued by Thermo Fisher Scientific (Finance I) B.V., its indirect, wholly-owned finance subsidiary: €1,000,000,000 aggregate principal amount of its floating rate senior notes due 2027 (the “floating rate notes”) at the issue price of 100.000%...

Thermo Fisher Scientific’s Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small Cell Lung Cancer

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic (CDx) to identify patients who may be eligible for treatment with HYRNUO™ (sevabertinib), a new HER2-directed therapy developed and commercialized by Bayer. The test enables clinicians and pathologists to identify non-small cell lung cancer (NSCLC) tumors wi...
Back to Newsroom